SMO and meningioma: Recent genomic studies of meningiomas have elucidated a rich array of recurrent non NF2 mutations, typically in TNF receptor-associated factor 7 (TRAF7), Kruppel-like factor 4 (KLF4), v-Akt murine thymoma viral oncogene homolog 1 (AKT1), RNA polymerase II subunit A (POLR2A), Telomerase reverse transcriptase (TERT), smoothened/frizzled class receptor (SMO), and Phosphadidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) (Table 2) [12,50,84,85].